Eli Lilly announced a cash‑only acquisition of privately held Kelonia Therapeutics for up to $7 billion, including an upfront payment of $3.25 billion. The deal is expected to close in the second half of 2026 and will add Kelonia’s proprietary in‑vivo gene‑delivery platform, iGPS®, to Lilly’s oncology portfolio.
The acquisition is a strategic move to broaden Lilly’s oncology pipeline beyond its successful weight‑loss and diabetes products. Kelonia’s platform delivers a one‑time intravenous gene therapy that could overcome the manufacturing, safety, and access barriers that limit the reach of current ex‑vivo CAR‑T treatments. The lead program, KLN‑1010, is an investigational therapy for multiple myeloma that has shown a 100 % minimal residual disease‑negative response rate in the first four patients treated in a Phase 1 trial.
The transaction structure includes a $3.25 billion upfront cash payment and potential milestone payments up to $7 billion, tied to clinical, regulatory, and commercial milestones. The upfront cash reflects Lilly’s confidence in the platform’s commercial potential and its fit with Lilly’s existing oncology capabilities.
Management highlighted the strategic fit and early clinical promise. Jacob Van Naarden, Lilly’s executive vice president of oncology, said, "Autologous CAR‑T therapies have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them. Kelonia's in vivo platform has the potential to change that by delivering rapid, durable responses in a far simpler, off‑the‑shelf format." Van Naarden added, "The early clinical data for KLN‑1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform. We look forward to working together with the Kelonia team to rapidly advance KLN‑1010 to address patient need and recognize the full potential of their platform in other conditions where patients may benefit." Kevin Friedman, Kelonia’s CEO, noted, "Kelonia's leadership in advancing the immense promise of in vivo cell therapy is unmatched, extending its reach and impact beyond the traditional boundaries of personalized medicine." Friedman also said, "We have demonstrated the ability to achieve deep multiple myeloma remissions with significantly reduced complexity and cost relative to ex vivo CAR T‑cell approaches. In combination with Lilly's strengths, our in vivo iGPS platform is positioned to broaden the reach of cell therapy beyond the current CAR‑T landscape in hematologic malignancies and to transform treatment across a far wider range of cancers and other serious diseases."
Investors reacted positively to the announcement, citing the expansion of Lilly’s oncology pipeline and the potential of the in‑vivo CAR‑T platform. The deal was viewed as a strategic complement to Lilly’s recent momentum in its GLP‑1 weight‑loss franchise, while some analysts noted short‑term concerns about the cost of the acquisition and regulatory scrutiny of the obesity drug. Overall, the market viewed the transaction as a long‑term growth catalyst for Lilly’s oncology business.
The acquisition follows Lilly’s February 2026 purchase of Orna Therapeutics for up to $2.4 billion and positions the company in a competitive race with other major pharma players such as Gilead, AbbVie, and Bristol Myers Squibb, all investing heavily in in‑vivo CAR‑T technology. By adding a platform that could deliver one‑time intravenous treatments, Lilly aims to capture a larger share of the rapidly expanding CAR‑T market, which is projected to reach tens of billions of dollars in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.